WOMEN'S ROGAINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for WOMEN'S ROGAINE (WOMEN'S ROGAINE).
Topical minoxidil is a potassium channel opener; it increases cutaneous blood flow and stimulates hair follicle growth by prolonging the anagen phase and enlarging miniaturized hair follicles.
| Metabolism | Minoxidil undergoes hepatic metabolism primarily via glucuronidation; about 20% is excreted unchanged in urine. |
| Excretion | Minoxidil is primarily metabolized in the liver. Approximately 20% of an oral dose is excreted unchanged in urine, and the remainder as metabolites. Fecal excretion accounts for <3%. After topical application, systemic absorption is low; absorbed drug follows same excretion routes. |
| Half-life | Terminal elimination half-life of minoxidil is approximately 4.2 hours (range 2.9–7.4 hours) after oral administration. Clinically, the hypotensive effect lasts longer due to tissue binding. For topical minoxidil, the half-life is similar but clinical effect on hair growth requires weeks to months. |
| Protein binding | Minoxidil is approximately 20% bound to plasma proteins, with no significant binding to albumin or specific proteins. |
| Volume of Distribution | Volume of distribution is approximately 3.3–5.7 L/kg, indicating extensive tissue distribution and binding to vascular smooth muscle. |
| Bioavailability | Oral minoxidil has a bioavailability of approximately 90%. Topical minoxidil (5% solution) has a systemic bioavailability of about 1.4–1.6% of the applied dose due to limited percutaneous absorption. |
| Onset of Action | For hypertension (oral): reduction in blood pressure occurs within 30 minutes, maximal effect at 2-3 hours. For hair regrowth (topical): visible results typically after 4 months or more of twice-daily application. |
| Duration of Action | Antihypertensive effect of oral minoxidil lasts approximately 24 hours, supporting once-daily dosing. For hair regrowth, continuous use is required; discontinuation leads to reversal of effect within 3-4 months. |
| Molecular Weight | 209.25 |
Topical: 1 mL of 5% minoxidil solution applied to the scalp twice daily. Maximum total daily dose: 2 mL (100 mg minoxidil).
| Dosage form | AEROSOL, FOAM |
| Renal impairment | For GFR <10 mL/min: not recommended; for GFR 10-29 mL/min: use with caution and consider dose reduction; for GFR ≥30 mL/min: no adjustment necessary. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: use with caution; Child-Pugh Class C: not recommended due to increased risk of systemic absorption. |
| Pediatric use | Not approved for use in pediatric patients (<18 years). Safety and efficacy not established. |
| Geriatric use | No specific dose adjustment required; monitor for potential increased systemic absorption due to thinner skin or decreased hepatic clearance. |
| 1st trimester | Minoxidil is not recommended in the first trimester due to insufficient data and potential risk of fetal hypotrichosis based on animal studies. |
| 2nd trimester | Avoid use in the second trimester for hair loss unless clearly needed; minimal systemic absorption expected with topical application. |
| 3rd trimester | Avoid use in the third trimester; due to possible hypotensive effects in the mother and unknown fetal risks. |
Clinical note
Comprehensive clinical and safety monograph for WOMEN'S ROGAINE (WOMEN'S ROGAINE).
| Placental transfer | Minoxidil crosses the placenta in animal studies; extent in humans is unknown but expected due to low molecular weight. |
| Breastfeeding | Minoxidil is excreted in human milk; however, concentrations are low and not expected to cause adverse effects in the infant due to poor oral bioavailability. Use with caution. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to minoxidil or any component of the formulationApplication to broken or irritated scalp skin
| Precautions | May cause cardiac effects such as tachycardia and fluid retention if absorbed systemically; avoid application to broken or irritated skin; discontinue if scalp irritation occurs; monitor for increased hair loss or systemic effects. |
| Food/Dietary | No known food interactions. Avoid excessive caffeine or alcohol which may exacerbate hair loss indirectly. No dietary restrictions required. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Topical minoxidil (5%) has not been associated with significant teratogenicity in animal studies. Systemic absorption is minimal (approx 1.4%); however, data in pregnant women are limited. No increased risk of fetal malformations has been reported. Use only if clearly needed; avoid first trimester unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure and heart rate periodically due to potential for systemic effects. Fetal monitoring not routinely required; however, assess for signs of fluid retention or hypotension in mother. Ultrasound may be considered if high-dose exposure. |
| Fertility Effects | No known adverse effects on fertility in animal studies or human data. Topical application with minimal systemic absorption makes significant impact unlikely. |
| Women's Rogaine (minoxidil 5% foam) is FDA-approved for female pattern hair loss (androgenetic alopecia). Onset of action typically 4-6 months; initial shedding may occur in first weeks. Use on dry scalp; avoid concurrent use of other topical products for 1 hour. Contraindicated in pregnancy category C. Need for lifelong therapy to maintain effect. |
| Patient Advice | Apply 1/2 capful (1g) of foam to dry scalp once daily, spread over affected area. · Do not wash hair or apply other products for at least 1 hour after application. · Initial temporary hair shedding is normal and indicates drug is working. · Visible results may take 4-6 months; use consistently to maintain benefit. · Stop use if scalp irritation or unwanted facial hair growth occurs. · Keep away from children and pets; consult doctor if pregnant or breastfeeding. |